Skip to Content
Not all colorectal cancer treatments are the same. Find out more >

Sylatron (peginterferon alfa-2b) Disease Interactions

There are 9 disease interactions with Sylatron (peginterferon alfa-2b):

Major

Peginterferon Alfa (Includes Sylatron) ↔ Autoimmune Hepatitis

Severe Potential Hazard, Moderate plausibility

Applies to: Autoimmune Hepatitis

The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.

Major

Peginterferon Alfa (Includes Sylatron) ↔ Depression

Severe Potential Hazard, High plausibility

Applies to: Depression

Life-threatening or fatal neuropsychiatric reactions have been reported in patients receiving peginterferons alfa, including suicide, suicide ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose. These reactions have occurred in patients with and without previous psychiatric illness. These drugs should be used with extreme caution in patients with a history of depression. Other events reported include aggressive behavior, psychosis, hallucinations, bipolar disorder and mania. Patients should be monitored for any evidence of depression or other psychiatric symptoms, and they should be advised to report any signs or symptoms of depression or other changes in mood or behavior. In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.

Major

Peginterferon Alfa (Includes Sylatron) ↔ Severe Hepatic Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Cirrhosis, HIV Infection

The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.

Major

Peginterferon Alfa-2B (Includes Sylatron) ↔ Hemoglobinopathies

Severe Potential Hazard, Moderate plausibility

Applies to: Thalassemia, Sickle Cell Anemia, Hemoglobinopathy

The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.

Major

Peginterferon Alfa-2B (Includes Sylatron) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of peginterferon alfa-2b is contraindicated in patients with creatinine clearance less than 50 mL/min.

Moderate

Peginterferon Alfa (Includes Sylatron) ↔ Bone Marrow Suppression

Moderate Potential Hazard, Moderate plausibility

Applies to: Thrombocytopenia, Anemia

Peginterferons alfa suppress bone marrow function and may result in severe cytopenias. Very rarely, it may be associated with aplastic anemia. These drugs should be used with caution in patients with baseline neutrophil counts less than 1,500 cells/mm3, with platelet counts less than 90,000 cells/mm3 or baseline hemoglobin less than 10 g/dL. It is advised that complete blood counts be obtained pretreatment and monitored routinely during therapy. Neutropenia and thrombocytopenia occur with greater incidence in patients coinfected with HIV.

Moderate

Peginterferon Alfa (Includes Sylatron) ↔ Endocrine Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Thyroid Disease, Diabetes Mellitus, Hypoglycemia

Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus. Treatment should be administered with caution on patients with these conditions. Treatment should not be initiated if the condition cannot be effectively treated by medication. Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.

Moderate

Peginterferon Alfa (Includes Sylatron) ↔ Ophthalmological Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Visual Defect/Disturbance, Retinal Disorder

Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons. All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders. Patients should have periodic ophthalmologic exams during treatment.

Moderate

Peginterferon Alfa (Includes Sylatron) ↔ Pancreatitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Pancreatitis

Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon. Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.

Sylatron (peginterferon alfa-2b) drug Interactions

There are 188 drug interactions with Sylatron (peginterferon alfa-2b)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide